Protalix BioTherapeutics Inc (AMEX:PLX) price on Friday, April 11, rose 4.33% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $2.41.
A look at the stock’s price movement, the close in the last trading session was $2.31, moving within a range at $2.32 and $2.43. The beta value (5-Year monthly) was 0.456 while the PE ratio in trailing twelve months stood at 91.63. Turning to its 52-week performance, $2.76 and $0.82 were the 52-week high and 52-week low respectively. Overall, PLX moved 11.06% over the past month.
Protalix BioTherapeutics Inc’s market cap currently stands at around $188.06 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Mar-16.
Analysts have a consensus estimate of 21.6M for the company’s revenue for the quarter, with a low and high estimate of 21.6M and 21.6M respectively. The average forecast suggests up to a 487.44% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 80.49M, representing a 50.73% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that PLX is a 50% Buy. On the other hand, the stock is on average a 50% Buy as suggested by medium term indicators while long term indicators are putting the stock in 100% Buy category.
PLX’s current price about -1.69% and -1.28% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 49.65, while 7-day volatility ratio is 8.67% and 6.85% in the 30-day chart. Further, Protalix BioTherapeutics Inc (PLX) has a beta value of 0.04, and an average true range (ATR) of 0.15.
If we refocus on Protalix BioTherapeutics Inc (AMEX:PLX), historical trading data shows that trading volumes averaged 0.64 over the past 10 days and 677.30K over the past 3 months. The company’s latest data on shares outstanding shows there are 75.85 million shares.
The 7.51% of Protalix BioTherapeutics Inc’s shares are in the hands of company insiders while institutional holders own 6.63% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 0.65 million on 2025-03-14, giving us a short ratio of 0.99. The data shows that as of 2025-03-14 short interest in Protalix BioTherapeutics Inc (PLX) stood at 86.99999999999999 of shares outstanding, with shares short falling to 4.79 million registered in 2025-02-14. Current price change has pushed the stock 28.19% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the PLX stock continues to rise going into the next quarter.
